Is Ruxolitinib a chemotherapy drug?

Ruxolitinib is a prescription drug available in pill form that is used to treat adults with polycythemia vera who already take a drug called hydroxyurea but it doesn't work well enough or they can't tolerate it. Ruxolitinib tablets are the first drug approved by the U.S. Food and Drug Administration (FDA) to treat these patients. Ruxolitinib tablets are not chemotherapy drugs. It is a targeted treatment that helps control the production of blood cells.

Ruxolitinib tablets are a targeted therapy that work by targeting the JAK produced by blood cells. Ruxolitinib helps reduce overactive JAK signaling to help control blood cell production and may also help shrink an enlarged spleen. There is evidence that proteins called Janus kinases, or JAKs, are involved. JAK proteins send signals that affect the production of blood cells in the bone marrow. When JAKs send out too many signals, they cause the body to produce the wrong number of blood cells.

Ruxolitinib tabletsThe original drug has been launched in China and is included in the scope of Class B medical insurance. It is limited to patients who meet the indications. Specification The price of each box of 5mg*60 tablets may be around RMB 3,000. The Turkish version of ruxolitinib tablets listed overseas, Specifications20mg*56 tablets, may be priced around RMB 8,000 per box (the price may fluctuate due to exchange rates). There are also ruxolitinib tablets produced in other countries. For example, the price of 5mg*50 tablets produced by Bangladesh Yaopin International may be around 1,400 yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of domestic and foreign original drugs.